Daiichi Sankyo (OTCMKTS:DSNKY) Issues Earnings Results

Daiichi Sankyo (OTCMKTS:DSNKY) posted its quarterly earnings data on Friday. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.21 by $0.08, Zacks reports. The firm had revenue of $3.77 billion during the quarter, compared to analyst estimates of $3.58 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%.

Daiichi Sankyo Trading Up 5.3%

Shares of DSNKY opened at $17.44 on Friday. Daiichi Sankyo has a twelve month low of $14.98 and a twelve month high of $24.77. The stock has a market cap of $32.49 billion, a PE ratio of 17.80, a P/E/G ratio of 1.86 and a beta of -0.11. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The business’s 50-day moving average price is $17.77 and its 200-day moving average price is $17.66.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on DSNKY shares. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Daiichi Sankyo has a consensus rating of “Reduce”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.